172 related articles for article (PubMed ID: 32161722)
1. The Optimal Outcome of Suppressing Ewing Sarcoma Growth
Li DF; Yuan Y; Tu MJ; Hu X; Li YZ; Yi WR; Li PC; Zhao Y; Cheng Z; Yu AM; Jian C; Yu AX
Front Oncol; 2020; 10():222. PubMed ID: 32161722
[TBL] [Abstract][Full Text] [Related]
2. Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest.
Zhao Y; Tu MJ; Wang WP; Qiu JX; Yu AX; Yu AM
Sci Rep; 2016 May; 6():26611. PubMed ID: 27216562
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.
Zhao Y; Tu MJ; Yu YF; Wang WP; Chen QX; Qiu JX; Yu AX; Yu AM
Biochem Pharmacol; 2015 Dec; 98(4):602-13. PubMed ID: 26518752
[TBL] [Abstract][Full Text] [Related]
4. Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy.
Ho PY; Duan Z; Batra N; Jilek JL; Tu MJ; Qiu JX; Hu Z; Wun T; Lara PN; DeVere White RW; Chen HW; Yu AM
J Pharmacol Exp Ther; 2018 Jun; 365(3):494-506. PubMed ID: 29602831
[TBL] [Abstract][Full Text] [Related]
5. Bioengineered miR-34a modulates mitochondrial inner membrane protein 17 like 2 (MPV17L2) expression toward the control of cancer cell mitochondrial functions.
Yi WR; Tu MJ; Yu AX; Lin J; Yu AM
Bioengineered; 2022 May; 13(5):12489-12503. PubMed ID: 35579419
[TBL] [Abstract][Full Text] [Related]
6. Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization.
Wang WP; Ho PY; Chen QX; Addepalli B; Limbach PA; Li MM; Wu WJ; Jilek JL; Qiu JX; Zhang HJ; Li T; Wun T; White RD; Lam KS; Yu AM
J Pharmacol Exp Ther; 2015 Aug; 354(2):131-41. PubMed ID: 26022002
[TBL] [Abstract][Full Text] [Related]
7. A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma.
Alegre F; Ormonde AR; Snider KM; Woolard K; Yu AM; Wittenburg LA
PLoS One; 2018; 13(12):e0209941. PubMed ID: 30596759
[TBL] [Abstract][Full Text] [Related]
8. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
[TBL] [Abstract][Full Text] [Related]
9. [miR-34a-5p regulates viability, invasion and apoptosis of placental trophoblastic cells
Li Q; Xu J
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Jan; 40(1):79-86. PubMed ID: 32376568
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-34a-5p: A pivotal therapeutic target in gallbladder cancer.
Oda T; Tsutsumi K; Obata T; Ueta E; Kikuchi T; Ako S; Fujii Y; Yamazaki T; Uchida D; Matsumoto K; Horiguchi S; Kato H; Okada H; Chijimatsu R; Otsuka M
Mol Ther Oncol; 2024 Mar; 32(1):200765. PubMed ID: 38596294
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Peptide- and Lipid-Based Delivery of miR-34a-5p Mimic into PPC-1 Cells.
Urgard E; Brjalin A; Langel Ü; Pooga M; Rebane A; Annilo T
Nucleic Acid Ther; 2017 Oct; 27(5):295-302. PubMed ID: 28657476
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the diagnostic and therapeutic roles of non-coding RNA and cell proliferation related gene association in hepatocellular carcinoma.
Ahmed MY; Salah MM; Kassim SK; Abdelaal A; Elayat WM; Mohamed DA; Fouly AE; Abu-Zahra FAE
Gene; 2019 Jul; 706():97-105. PubMed ID: 31034943
[TBL] [Abstract][Full Text] [Related]
13. Single bioengineered ncRNA molecule for dual-targeting toward the control of non-small cell lung cancer patient-derived xenograft tumor growth.
Petrek H; Yan Ho P; Batra N; Tu MJ; Zhang Q; Qiu JX; Yu AM
Biochem Pharmacol; 2021 Jul; 189():114392. PubMed ID: 33359565
[TBL] [Abstract][Full Text] [Related]
14. Novel RNA molecular bioengineering technology efficiently produces functional miRNA agents.
Traber GM; Yi C; Batra N; Tu MJ; Yu AM
RNA; 2024 May; 30(6):680-694. PubMed ID: 38429100
[TBL] [Abstract][Full Text] [Related]
15. NFIX Circular RNA Promotes Glioma Progression by Regulating miR-34a-5p via Notch Signaling Pathway.
Xu H; Zhang Y; Qi L; Ding L; Jiang H; Yu H
Front Mol Neurosci; 2018; 11():225. PubMed ID: 30072869
[No Abstract] [Full Text] [Related]
16. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.
Gao J; Li N; Dong Y; Li S; Xu L; Li X; Li Y; Li Z; Ng SS; Sung JJ; Shen L; Yu J
Oncogene; 2015 Jul; 34(31):4142-52. PubMed ID: 25362853
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2.
Ma S; Fu T; Zhao S; Gao M
Eur J Pharmacol; 2019 Jun; 852():42-50. PubMed ID: 30851271
[TBL] [Abstract][Full Text] [Related]
18. Down-Regulation of miR-34a-5p Potentiates Protective Effect of Adipose-Derived Mesenchymal Stem Cells Against Ischemic Myocardial Infarction by Stimulating the Expression of C1q/Tumor Necrosis Factor-Related Protein-9.
Weng CF; Wu CF; Kao SH; Chen JC; Lin HH
Front Physiol; 2019; 10():1445. PubMed ID: 31920683
[TBL] [Abstract][Full Text] [Related]
19. NEAT1 regulates cell proliferation and apoptosis of ovarian cancer by miR-34a-5p/BCL2.
Ding N; Wu H; Tao T; Peng E
Onco Targets Ther; 2017; 10():4905-4915. PubMed ID: 29062236
[TBL] [Abstract][Full Text] [Related]
20. c-Myc, RMRP, and miR-34a-5p form a positive-feedback loop to regulate cell proliferation and apoptosis in multiple myeloma.
Xiao X; Gu Y; Wang G; Chen S
Int J Biol Macromol; 2019 Feb; 122():526-537. PubMed ID: 30389523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
